ProBioGen and Minapharm Enter into Development and Co-promotion Agreements
In the second agreement, ProBioGen and Minapharm will co-develop a second generation biopharmaceutical product using either ProBioGen's pre-optimised CHO cell line or its proprietary Human Neuronal Cell Line AGE1.HN. Minapharm will exclusively market the product in Middle Eastern and African countries while ProBioGen will have promotional rights in Rest of the World. Both companies will also share the revenue from the product. Further financial details are not disclosed.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.